-
Most Recent
Search Results
240 results for cmo
Netflix, Inc. Won’t Languish Long If the Bulls Have Their Way (NFLX)
The market may worry about cost concerns and troubles going global, but investor sentiment in Netflix (NFLX) is too strong to be broken.
The Dip Before the Next AI Boom
Stocks slid this week, with tech taking most of the hit. On Thursday, the S&P 500 fell for a fifth straight day, and the Nasdaq…
Eyenovia News: Why EYEN Stock Is Skyrocketing 33% Today
Eyenovia (EYEN) is in the news Tuesday after an exclusive deal with Arctic Vision for two of its treatments sent EYEN stock soaring higher.
Biogen Inc Stock Shoots Higher on Alzheimer’s Drug Trial
Biogen (BIIB) stock was soaring today on positive results from a recent Alzheimer’s drug trial conducted along with Eisai.
Powell at Jackson Hole + 13 Big Stock Questions This Week
The annual Jackson Hole Economic Policy Symposium is set to kick off on Thursday. And with the likelihood of a September interest rate cut rising,…
MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500
Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN).
Why Is Longeveron (LGVN) Stock on the Move Today?
Longeveron (LGVN) stock is on the move Wednesday after the FDA granted its fast-track designation for heart treatment Lomecel-B.
CRWD Stock Alert: What to Know About CrowdStrike’s New President
CrowdStrike (CRWD) stock is in the news Wednesday as the cybersecurity company announced Michael Sentonas as its new president.
What to Expect for Energy, REITs and Finance Investments
As the end of the year approaches, investors will want to stay on top of the latest guidance in the energy, real estate and finance…
Vertex Pharmaceuticals News: Why VRTX Stock Is Getting Slammed 20% Today
Vertex Pharmaceuticals (VRTX) news for Thursday concerning bad results from one of its clinical trials is sending VRTX stock down.
RUBY Stock Alert: The Promising Cancer Drug News That Has Rubius Therapeutics Rocketing Today
Rubius Therapeutics (RUBY) stock was flying high on Monday after announcing early results from a clinical trial of its new cancer treatment.
RIVN Stock Analysis: The Bull and Bear Case for Betting on Rivian
According to this RIVN stock analysis, Rivian and RIVN stock could be worth buying as a speculative bet here.
Will ‘Sell in May and Go Away’ Take Hold in 2013 After All?
S&P 500 charts from the past decade illustrate why we shouldn’t start panicking about the recent market turbulence.
3 Small-Cap Dividend Stocks With Big Yields
Big, regular income checks plus a chance for share appreciation? Sounds like a winning combination to me.
AI Is Minting New Billionaires – Here’s How to Join Them
More AI also equals more billion-dollar tech companies… and, thanks to their high valuations, more billionaires. And I want to teach you how to stay…
Algorand Price Predictions: What’s Next for the ALGO Crypto?
Algorand (ALGO) price predictions are worth checking on Thursday as traders react to positive news concerning the crypto.
Why Is Pliant Therapeutics (PLRX) Stock Up 62% Today?
Pliant Therapeutics (PLRX) stock is taking off on Monday after releasing positive Phase 2a clinical trial data for bexotegrast.
Target Corporation: TGT Stock Is a Great Contrarian Play
Target has struggled this year, but restructuring and plans to expand online sales and grocery options could be just what TGT stock needs.
BNGO Stock: 9 Reasons Why Bionano Genomics Shares Are Getting a Boost Today
Bionano Genomics (BNGO) stock is on the rise Wednesday as investors react to news announced by the company after markets closed on Tuesday.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It’s time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
LCID Stock: Why Luxury EV Maker Lucid Is Running Out of Road
The Lucid Air is a billionaire’s electric ride, but there aren’t enough billionaires for Lucid to make a profit serving them.
The Secret Sauce Fueling Palantir Stock’s Meteoric Rise
Palantir stock has lost nearly 20% since hitting an all-time high in early March. It could be time to buy given its AIP platform’s growth.
6 – 10 of 240 results
